Skip to main content

Elucirem FDA Approval History

Last updated by Judith Stewart, BPharm on Oct 2, 2022.

FDA Approved: Yes (First approved September 21, 2022)
Brand name: Elucirem
Generic name: gadopiclenol
Dosage form: Injection
Company: Guerbet
Treatment for: Diagnosis and Investigation

Elucirem (gadopiclenol) is a macrocyclic gadolinium-based contrast agent (GBCA) for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the CNS and the body.

Development timeline for Elucirem

Sep 21, 2022Approval FDA Approves Elucirem (gadopiclenol) for Contrast-Enhanced Magnetic Resonance Imaging (MRI)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.